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High-sensitivity troponin assays and
the early rule-out of acute myocardial
infarction
Anoop S V Shah, David E Newby, Nicholas L Mills
Many patients self-present or are referred
by primary care to the emergency depart-
ment with chest pain because of the
potential that they may be suffering an
acute myocardial infarction, one of the
most common causes of death world-
wide.1 Owing to diagnostic uncertainty,
the majority of these patients are admit-
ted, and, in some centres, chest pain is
responsible for up to 40% of all
unplanned hospital admissions.2 The
majority of these admissions are unneces-
sary and place additional burden on
healthcare systems that are already strug-
gling to cope with increasing emergency
care attendances. Approaches to improve
the accurate identiﬁcation of patients with
myocardial infarction would therefore be
welcome and a potential major beneﬁt.
Cardiac troponins are regulatory muscle
proteins that are released into the circulation
after acute myocardial injury. Assays that
quantify cardiac isoforms of troponin have
greater speciﬁcity and sensitivity for the
diagnosis of myocardial infarction than trad-
itional cardiac enzymes.3 4 Recent advances
have led to greatly improved assay sensitiv-
ity, permitting quantiﬁcation of extremely
low serum concentrations of troponin with
excellent precision. High-sensitivity cardiac
troponin assays have limits of detection 10–
100-fold lower than contemporary assays
and are able to detect troponin in the circu-
lation of the majority of healthy persons.4
These assays have the potential to transform
how we assess patients with chest pain in
the emergency room.
Myocardial infarction is deﬁned as a
rise and/or fall in cardiac troponin with at
least one value above the 99th centile
upper reference limit in the context of
symptoms or clinical evidence of myocar-
dial ischaemia.5 To minimise the potential
for misdiagnosis, the National Institute
for Health and Clinical Excellence
(NICE) guidelines have recommended
measuring troponin on admission and
10–12 h after the onset of symptoms to
coincide with the peak in circulating
troponin concentration.6 These guidelines
now need updating to reﬂect the more
widespread use of high-sensitivity tropo-
nin assays in the clinic. Indeed the latest
guidelines from the Global Task Force rec-
ommend that troponin concentrations
should be determined on admission and
at 3–6 h after admission, irrespective of
the timing of onset of symptoms.5 7 More
sensitive assays permit the detection of
smaller amounts of myocardial injury and
therefore enable the clinician to make an
earlier diagnosis.
Hoeller and colleagues have addressed
an important and clinically relevant ques-
tion.8 Can high-sensitivity troponin assays
be used to rule out myocardial infarction
with a single measurement of troponin on
presentation? This strategy is not
endorsed by international guidelines and
the answer to the question is unequivocal.
Troponin concentrations on presentation
were within the normal reference range in
up to one-ﬁfth of patients who would sub-
sequently be diagnosed with acute myo-
cardial infarction on repeat sampling.
Indeed in patients presenting with symp-
toms for <3 h, as many as one in two
patients with a diagnosis of myocardial
infarction had troponin concentrations
within the normal reference range on
presentation. In these patients, the diagno-
sis would have been missed if clinicians
were to rely on a single measurement of
troponin in the emergency department,
and the authors conclude that serial sam-
pling is essential for the diagnosis of myo-
cardial infarction.
One of the strengths of the analysis of
Hoeller and colleagues is that they evaluate
four high-sensitivity assays including two
prototype assays that are not yet commer-
cially available. They report differences
between assays in the sensitivity of a single
admission troponin concentration for a
ﬁnal diagnosis of myocardial infarction
determined on serial testing that, if inter-
preted incorrectly, could infer advantages
or disadvantages of one assay over
another. Apparent differences in sensitivity
between assays are not due to differences in
assay precision, but are a consequence of
variance in the manufacturers’ recom-
mended 99th centile upper reference limits
and the selection of one assay for adjudica-
tion of the ﬁnal diagnosis. The analysis
would have been more meaningful if the
ﬁnal diagnosis was adjudicated for each
assay in turn or if the upper reference
limits, and therefore diagnostic thresholds,
were determined for each assay in a single
reference population. A recent independent
normal reference range study has made a
major contribution in this area, reporting
upper reference limits that were 3- and
5-fold higher than the manufacturers’ limits
for the prototype assays used in the present
analysis.9 Hoeller and colleagues also high-
light the value of standardisation for
cardiac troponin assays. We believe all high-
sensitivity cardiac troponin assays should be
evaluated in a large independent, multi-
ethnic, age- and sex-varied reference popu-
lation to determine the normal range as
part of the regulatory approval process.
Serial sampling of troponin is important
not just to permit the safe rule-out of myo-
cardial infarction, but also to minimise the
potential for misdiagnosis in patients with
elevated cardiac troponin concentrations.
Improvements in assay sensitivity have inev-
itably reduced speciﬁcity for myocardial
infarction, as these assays do not deﬁne the
cause of myocardial injury. Troponin con-
centrations may be outwith the normal ref-
erence range in patients with other acute
illnesses and in patients with chronic struc-
tural heart diseases, including stable coron-
ary artery disease10 and congestive cardiac
failure.11 12 It is therefore essential to dem-
onstrate a rise and/or fall in troponin con-
centration to differentiate acute myocardial
infarction from acute or chronic myocardial
injury.5 7
Innovative algorithms to rule out myo-
cardial infarction in the emergency depart-
ment based on thrombolysis in myocardial
infarction (TIMI) risk score and serial
troponin measurement at presentation and
2 h later may permit an additional 40% of
patients to be safely discharged.13 Indeed
the use of more sensitive assays and earlier
detection of myocardial necrosis does
improve clinical outcomes.14 The value for
the patient, clinician and hospital of a rapid
diagnosis is clear, but needs to be offset
against the identiﬁcation of increasing
numbers of patients with elevated troponin
concentrations due to non-acute coronary
syndrome pathologies.15 Hoeller and col-
leagues’ use of the manufacturers’ recom-
mended upper reference limits, as low as
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9 ng/L for two prototype cardiac troponin I
assays, highlights the potential for harm.
For every patient with an admission tropo-
nin concentration >9 ng/L correctly diag-
nosed with myocardial infarction, another
patient who did not have acute myocardial
infarction was identiﬁed. As such, the posi-
tive predictive value of an elevated admis-
sion troponin concentration was as low as
45% even in a well-selected population of
patients with symptoms suggestive of myo-
cardial infarction. When these assays are
used more widely in the emergency depart-
ment, the use of inappropriate diagnostic
thresholds that have not been independ-
ently validated have the potential to result
in widespread misdiagnosis, unnecessary
hospitalisation and investigation, with a det-
rimental effect on clinical outcomes that
may undermine the beneﬁts of an earlier
diagnosis of myocardial infarction.
The work of Hoeller and colleagues is
important and highlights the need for
assay standardisation, robust independent
assessment of the normal reference range
using an appropriate reference population,
and the need for careful evaluation of the
impact of high-sensitivity cardiac troponin
assays on clinical care.
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